CycloLab

CycloLab is a well-established, private Hungarian biotech with a 30-year legacy in cyclodextrin technology. It has a dual business model combining the sale of a broad portfolio of cyclodextrin derivatives with contract research and development services for various industries. The company is advancing an internal pipeline, including a novel cyclodextrin-based API for Niemann-Pick C disease and a reformulation program for lonafarnib, while seeking partners for clinical development. Its core strength lies in its extensive library of cyclodextrin compounds and GMP manufacturing capabilities.

Proprietary library of over 100 cyclodextrin derivatives for structure-activity relationship studies, enabling drug delivery, novel API discovery, and custom synthesis. Capabilities include GMP manufacturing of complex cyclodextrins like SBECD.

CycloLab competes with large chemical companies like Wacker Chemie and Roquette in the supply of standard cyclodextrins. Its differentiation lies in its vast library of exotic derivatives, strong custom synthesis and analytical services, and GMP capability for complex derivatives like SBECD. In the therapeutic space, it competes with other biotechs developing treatments for NPC and novel antiviral agents.